4D Molecular Therapeutics, Inc.
FDMT
$3.13
-$0.14-4.28%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -47.97M | -49.67M | -43.84M | -34.95M | -32.40M |
| Total Depreciation and Amortization | 1.75M | 1.78M | 1.70M | 1.62M | 1.59M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.63M | 5.74M | 4.29M | 3.77M | 5.24M |
| Change in Net Operating Assets | -7.17M | -3.72M | 8.46M | -688.00K | -3.52M |
| Cash from Operations | -47.76M | -45.86M | -29.39M | -30.24M | -29.09M |
| Capital Expenditure | -631.00K | -949.00K | -1.78M | -349.00K | -710.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 32.58M | 8.01M | 29.08M | -73.19M | -262.55M |
| Cash from Investing | 31.95M | 7.06M | 27.30M | -73.54M | -263.26M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 601.00K | 568.00K | 17.25M | 318.83M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 601.00K | 568.00K | 17.25M | 318.83M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -15.81M | -38.20M | -1.52M | -86.53M | 26.49M |